Skip to Content

Basilea Pharmaceutica Ltd BPMUF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Basilea Pharmaceutica Ltd is a biotechnology company that focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology. The company aims to develop drugs in order to target the medical challenge of resistance and non-response to current treatment options. Basilea generates its revenue from the European countries and the United States, while utilizing distribution agreements for the Middle East and North Africa regions. The company's research strategy integrates the areas of genomics, cell biology, medicinal chemistry, and pharmacology. The research teams work closely together with scientists in Basilea China in their search for novel molecules with distinct advantages over available therapies.

Contact
Grenzacherstrasse 487
Basel, 4058, Switzerland
T +41 616061111
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Dec 31, 2020
Stock Type
Employees 225